在抑郁症中推进帕洛治疗:预测缓解和血度,并验证和更新治疗参考范围
Rui Yuan1, Yundan Liao1, Xuan Lu2
1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
Translational psychiatry
|August 28, 2025
概括
这项研究开发了模型来预测主要抑郁症 (MDD) 治疗缓解和帕洛克塞丁度. 较低的CYP2D6活性评分预测了帕洛的最佳水平,提高了治疗效率并减少了药物不良反应.
科学领域:
- 药物基因组学
- 临床药理学
- 精神病学
背景情况:
- 优化对重度抑郁症 (MDD) 的治疗需要准确的治疗效果预测模型和治疗药物监测 (TDM).
- 了解CYP2D6活性等遗传因素对帕洛的药理动力学的影响对于个性化治疗至关重要.
研究的目的:
- 在汉族MDD患者中开发帕洛治疗缓解和稳定状态度 (Css) 的预测模型.
- 调查CYP2D6活性评分 (AS) 在预测帕洛Css中的作用.
- 确定药物不良反应和Css之间的关联.
- 在该群体中验证和更新帕洛的治疗参考范围 (TRR).
主要方法:
- 一项涉及530名汉族MDD患者的前性队列研究的后期分析.
- 开发后勤回归模型以预测治疗缓解和Css.
- 通过对共变量进行调整的逻辑回归来评估ADR和Css关联.
- 接收器操作特征 (ROC) 分析以确定更新的TRR.
主要成果:
- 治疗缓解的预测模型达到0. 707的AUC;Css的模型具有0. 615的AUC.
- 帕洛西丁Css在20- 65ng/ ml范围内与更高的缓解率 (OR=1. 655) 和较低的副作用 (OR=0. 460) 相相关.
- 较低的CYP2D6AS与维持Css在治疗范围内的情况有关 (OR=0. 638).
- 更新的TRR为20. 8-52.5 ng/ ml,平衡了疗效和安全性.
结论:
- 在MDD患者中,CYP2D6 AS和Css是优化帕洛治疗的有价值预测因素.
- 更新的TRR为汉族人群中帕洛的TDM提供了更精细的指导方针.
- 这些发现支持个性化帕洛剂量策略,以改善临床结果和患者安全.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
563
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
563
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
293
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
293
Antidepressant Drugs: Overview
741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741
Electroconvulsive Therapy
182
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
182
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209


